Supplementary Figure S4 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer

Key Points

• HBS-101 effectively induces apoptosis in MDA-MB-231 and BT-549 cells via midkine inhibition.
• Flow cytometry confirmed increased Annexin V staining, marking apoptotic cell death post-treatment with HBS-101.
• Analysis was performed with established breast cancer cell lines, providing insights into potential therapeutic applications.
• The findings highlight the need for further investigation into HBS-101's efficacy as a treatment for triple-negative breast cancer.